RWJ-67657

inquiry

Cat No.

CEI-1105

Description

RWJ-67657 is a potent, orally active inhibitor of p38 mitogen-activated protein kinase. It selectively inhibits p38α and p38β over p38γ, p38δ and a range of other kinases. RWJ-67657 inhibits the release of TNF-α by lipopolysaccharide (a monocyte stimulus)-treated human peripheral blood mononuclear cells with an IC50 of 3 nM, as well as the release of TNF-α from peripheral blood mononuclear cells treated with the superantigen staphylococcal enterotoxin B (a T cell stimulus), with an IC50 of 13 nM. RWJ-67657 may have use as a treatment for inflammatory diseases.

Abbr

RWJ-67657(MAPK14)

Alias

RP1-179N16.5, CSBP, CSBP1, CSBP2, CSPB1, EXIP, Mxi2, PRKM14, PRKM15, RK, SAPK2A, p38, P38alpha

Product Overview

Inhibitor of p38 mitogen-activated protein kinase

CAS_No

215303-72-3

Molecular Weight

425.5

Purity

> 95%

Stability

2 years -20 centigrade Powder
1 month -4 centigrade in DMSO
More than one month -80 centigrade in DMSO

Storage

4 centigrade

Synonyms

RP1-179N16.5, CSBP, CSBP1, CSBP2, CSPB1, EXIP, Mxi2, PRKM14, PRKM15, RK, SAPK2A, p38, P38alpha

Targets

p38 MAP

Molecular Formula

C27H24FN3O

Chemical Name

4-(4-(4-fluorophenyl)-1-(3-phenylpropyl)-5-(pyridin-4-yl)-1H-imidazol-2-yl)but-3-yn-1-ol

Solubility

DMSO > 112mg/mL Water >1mg/mL Ethanol > 4mg/mL

Name:

Email *

Phone:*

Company/Institution:

Country or Region:

Quantity:

Services & Products Interested *

Project Description:

Our Products Cannot Be Used As Medicines Directly For Personal Use.

Products

Online Inquiry